/Bio-Techne%20ground%20sign%20outside%20of%20the%20office%20in%20San%20Jose%2C%20California%2C%20USA%20-%20June%208%2C%202023_%20By%20JHVEPhoto.jpeg)
Bio-Techne is scheduled to post its fourth-quarter results soon, and analysts project a single-digit earnings decline.
Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks
Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
NEW YORK , July 2, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Bio-Techne Corporation...
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
NEW YORK , June 26, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...
Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?